Literature DB >> 12823259

WF-536 inhibits metastatic invasion by enhancing the host cell barrier and inhibiting tumour cell motility.

Masahide Nakajima1, Ken-Ichi Katayama, Ichiro Tamechika, Kazutaka Hayashi, Yusaku Amano, Masayoshi Uehata, Nobuharu Goto, Takao Kondo.   

Abstract

1. Rho-associated coiled-coil forming protein serine/threonine kinase (ROCK) is involved in the development of tumour metastasis. Wf-536, (+)-(R)-4-(1-Aminoethyl)-N-(4-pyridyl) benzamide monohydrochloride, a novel inhibitor of ROCK, inhibits tumour metastasis in some animal models. To metastasise, tumour cells have to disturb the tight intercellular junctions and the basement membrane matrix of the host tissue, which, respectively, create an intercellular barrier and the extracellular membrane. To clarify the mechanism of Wf-536 in inhibition of tumour metastasis, we analysed the effect of Wf-536 on the transition of tumour cells through the host cell layer and the basement membrane in in vitro systems. 2. In a coculture system of human fibrosarcoma HT1080 cells plated on a monolayer of human ECV304 cells, Wf-536 (0.3-3 micromol/L) inhibited the paracellular infiltration of tumour cells. 3. Wf-536 (3-30 micromol/L) inhibited the invasion of tumour cells through the reconstituted basement membrane (Matrigel) layer. 4. Wf-536 (10-30 micromol/L) inhibited the migration of tumour cells. At 0.3-3 micromol/L, Wf-536 also restrained hepatocyte growth factor/scatter factor (HGF)-induced increases in paracellular permeability of the ECV304 cell layer. 5. These results suggest that Wf-536 suppresses tumour metastasis by both enhancing the barrier function of host cell layers and inhibiting tumour cell motility at the stage of host tissue penetration by metastatic tumour cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12823259     DOI: 10.1046/j.1440-1681.2003.03855.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  13 in total

1.  Afzelin exhibits anti-cancer activity against androgen-sensitive LNCaP and androgen-independent PC-3 prostate cancer cells through the inhibition of LIM domain kinase 1.

Authors:  Kai-Chang Zhu; Jian-Mei Sun; Jian-Guo Shen; Ji-Zhong Jin; Feng Liu; Xiao-Lin Xu; Lin Chen; Lin-Tao Liu; Jia-Ju Lv
Journal:  Oncol Lett       Date:  2015-08-18       Impact factor: 2.967

2.  A novel role of Rho-kinase in the regulation of ligand-induced phosphorylated EGFR endocytosis via the early/late endocytic pathway in human fibrosarcoma cells.

Authors:  Yukio Nishimura; Biborka Bereczky; Kiyoko Yoshioka; Shun'ichiro Taniguchi; Kazuyuki Itoh
Journal:  J Mol Histol       Date:  2011-08-17       Impact factor: 2.611

3.  Differential protein expression profiles in estrogen receptor-positive and -negative breast cancer tissues using label-free quantitative proteomics.

Authors:  Karim Rezaul; Jay Kumar Thumar; Deborah H Lundgren; Jimmy K Eng; Kevin P Claffey; Lori Wilson; David K Han
Journal:  Genes Cancer       Date:  2010-03

4.  ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion.

Authors:  Dominico Vigil; Tai Young Kim; Ana Plachco; Andrew J Garton; Linda Castaldo; Jonathan A Pachter; Hanqing Dong; Xin Chen; Brianna Tokar; Sharon L Campbell; Channing J Der
Journal:  Cancer Res       Date:  2012-08-31       Impact factor: 12.701

5.  Co-crystal structures of inhibitors with MRCKβ, a key regulator of tumor cell invasion.

Authors:  Timo Heikkila; Edward Wheatley; Diane Crighton; Ewald Schroder; Alexandra Boakes; Sarah J Kaye; Mokdad Mezna; Leon Pang; Mathew Rushbrooke; Andrew Turnbull; Michael F Olson
Journal:  PLoS One       Date:  2011-09-20       Impact factor: 3.240

6.  α-TEA inhibits the growth and motility of human colon cancer cells via targeting RhoA/ROCK signaling.

Authors:  Jialin Yao; Peng Gao; Yang Xu; Zhaozhu Li
Journal:  Mol Med Rep       Date:  2016-07-18       Impact factor: 2.952

7.  Investigation of Rho-Kinase Expressions and Polymorphisms in Mantle Cell Lymphoma Patients.

Authors:  Didar Yanardağ Açık; Mehmet Yılmaz; İbrahim Sarı; Serdar Öztuzcu; Zeynel A Sayıner; Salih Subari; Abdullah T Demiryürek
Journal:  Turk J Haematol       Date:  2015-08-06       Impact factor: 1.831

8.  Cardiac Safety of Kinase Inhibitors - Improving Understanding and Prediction of Liabilities in Drug Discovery Using Human Stem Cell-Derived Models.

Authors:  Ricarda Ziegler; Fabian Häusermann; Stephan Kirchner; Liudmila Polonchuk
Journal:  Front Cardiovasc Med       Date:  2021-06-16

Review 9.  Targeting Rho-GTPases in immune cell migration and inflammation.

Authors:  Maté Biro; Marcia A Munoz; Wolfgang Weninger
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

Review 10.  Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities.

Authors:  Venessa T Chin; Adnan M Nagrial; Angela Chou; Andrew V Biankin; Anthony J Gill; Paul Timpson; Marina Pajic
Journal:  Expert Rev Mol Med       Date:  2015-10-28       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.